Ind-Swift Laboratories Limited (NSE:INDSWFTLAB)
108.32
-1.85 (-1.68%)
Sep 11, 2025, 3:30 PM IST
Ind-Swift Laboratories Revenue
Ind-Swift Laboratories had revenue of 1.53B INR in the quarter ending June 30, 2025, with 360.51% growth. This brings the company's revenue in the last twelve months to 5.67B, down -43.47% year-over-year. In the fiscal year ending March 31, 2025, Ind-Swift Laboratories had annual revenue of 5.62B, down -56.70%.
Revenue (ttm)
5.67B
Revenue Growth
-43.47%
P/S Ratio
1.78
Revenue / Employee
120.73M
Employees
47
Market Cap
10.12B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 5.62B | -7.36B | -56.70% |
Mar 31, 2024 | 12.97B | 813.32M | 6.69% |
Mar 31, 2023 | 12.16B | 1.63B | 15.48% |
Mar 31, 2022 | 10.53B | 1.46B | 16.12% |
Mar 31, 2021 | 9.07B | 1.07B | 13.44% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 537.77B |
Divi's Laboratories | 96.52B |
Cipla | 274.80B |
Apollo Hospitals Enterprise | 225.51B |
Mankind Pharma | 129.10B |
Zydus Lifesciences | 236.08B |
Fortis Healthcare | 80.94B |
Alkem Laboratories | 133.04B |